%PDF-1.4
%
1 0 obj
<>>>
endobj
2 0 obj
<>stream
2017-01-16T13:15:06+05:30
2017-01-16T13:15:07+05:30
2017-01-16T13:15:07+05:30
Adobe InDesign CS6 (Macintosh)
uuid:91064a6b-e357-e946-ab1e-d343c1018ddc
xmp.did:01801174072068118DBB881A9EDFAAFA
xmp.id:8DE8C7D811206811822ACB128E595E5F
proof:pdf
converted
from application/x-indesign to application/pdf
Adobe InDesign CS6 (Macintosh)
/
2017-01-16T13:15:06+05:30
xmp.iid:273D30A90E206811822ACB128E595E5F
xmp.did:01801174072068118DBB881A9EDFAAFA
xmp.did:01801174072068118DBB881A9EDFAAFA
default
application/pdf
Adobe PDF Library 10.0.1
False
endstream
endobj
5 0 obj
<>
endobj
3 0 obj
<>
endobj
7 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
8 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
9 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
10 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
11 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
12 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
46 0 obj
<>stream
q
/GS0 gs
/Fm0 Do
Q
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
11 0 0 11 564.9999 45.4294 Tm
(37)Tj
ET
q
0 g
/GS0 gs
/Fm1 Do
Q
q
0 0 612 792 re
W n
BT
/T1_1 1 Tf
13 0 0 13 36 686.808 Tm
(R)Tj
9.1 0 0 9.1 44.6709 686.808 Tm
(EFE)Tj
/Span<>> BDC
(R)Tj
EMC
(ENCES)Tj
ET
Q
BT
/TT0 1 Tf
/Span<>> BDC
10 0 0 10 36 661.808 Tm
( )Tj
EMC
/T1_0 1 Tf
-0.03 Tc 0.03 Tw 0.5 0 Td
[(1)-30(.)]TJ
/Span<>> BDC
( )Tj
EMC
/T1_2 1 Tf
0 Tc 0.135 Tw 1.3 0 Td
[(T)79.8(an EM, Kalimullah E, Sohail MR, Ramar K. Diagnostic )]TJ
0.064 Tw 0 -1.2 TD
[(challenge in a patient with se)24.9(v)14.9(ere anion g)4.9(ap metabolic aci)]TJ
0 Tw (-)Tj
T*
(dosis. )Tj
/T1_3 1 Tf
[(Case Rep Crit Car)37(e)14.9(. )]TJ
/T1_2 1 Tf
(2015;2015:272914.)Tj
/T1_0 1 Tf
-0.03 Tc 0.28 Tw /Span<>> BDC
-1.8 -1.2 Td
( )Tj
EMC
[(2)-30(.)]TJ
/Span<>> BDC
( )Tj
EMC
/T1_2 1 Tf
0 Tc 0.26 Tw 1.8 0 Td
[(Mehta )54.6(AN)24.9(, Emmett JB)29.8(, Emmett M. GOLD MARK: an )]TJ
0.204 Tw T*
[(anion )0.5(g)4.9(ap mnemonic )0.5(for )0.5(the )0.5(21st )0.5(centur)-19.8(y)85(. )]TJ
/T1_3 1 Tf
0 Tw 18.297 0 Td
(Lancet. )Tj
/T1_2 1 Tf
3.426 0 Td
(2008;)Tj
( )Tj
-21.722 -1.2 Td
(372\(9642\):892.)Tj
/T1_0 1 Tf
-0.03 Tc 0.28 Tw /Span<>> BDC
-1.8 -1.2 Td
( )Tj
EMC
[(3)-30(.)]TJ
/Span<>> BDC
( )Tj
EMC
/T1_2 1 Tf
0 Tc 0.365 Tw 1.8 0 Td
[(Kamran H, Ram N)24.9(. Chronic acetaminophen use asso)]TJ
0 Tw (-)Tj
0.41 Tw T*
[(ciated with anion-g)4.9(ap metabolic acidosis. )]TJ
/T1_3 1 Tf
(Am J Med. )Tj
/T1_2 1 Tf
0 Tw T*
(2016;129\(8\):e127-128.)Tj
/T1_0 1 Tf
-0.03 Tc 0.28 Tw /Span<>> BDC
-1.8 -1.2 Td
( )Tj
EMC
[(4)-30(.)]TJ
/Span<>> BDC
( )Tj
EMC
/T1_2 1 Tf
0 Tc 0.034 Tw 1.8 0 Td
[(Zein JG, )29.6(W)79.8(allace DJ)59.8(, Kinase)24.9(witz G, )49.6(T)79.9(oubia N)24.9(, Kak)9.8(oulas C. )]TJ
0.06 Tw T*
[(Earl)24.9(y anion g)4.9(ap metabolic acidosis in acetaminophen o)44.9(v)14.9(er)]TJ
0 Tw 23.667 0 Td
(-)Tj
-23.667 -1.2 Td
(dose. )Tj
/T1_3 1 Tf
[(Am J Emer)25(g Med. )]TJ
/T1_2 1 Tf
(2010;28\(7\):798-802.)Tj
/T1_0 1 Tf
-0.03 Tc 0.28 Tw /Span<>> BDC
-1.8 -1.2 Td
( )Tj
EMC
[(5)-30(.)]TJ
/Span<>> BDC
( )Tj
EMC
/T1_2 1 Tf
0 Tc -0.039 Tw 1.8 0 Td
[(F)49.8(en)39.8(v)14.9(es )55.4(AZ, )0.5(Kirkpatrick )0.5(HM, )0.5(P)14.9(atel )50.3(VV)200(, )0.5(Sw)34.9(eetman )0.5(L, )0.5(Emmett )]TJ
0.18 Tw T*
[(M. Increased anion g)4.9(ap metabolic acidosis as a result of )]TJ
-0.001 Tw T*
[(5-o)19.8(xoproline \(p)29.8(yro)24.9(glutamic acid\): a role for acetaminophen. )]TJ
/T1_3 1 Tf
0 Tw T*
[(Clin J )59.8(Am Soc Nephr)45(ol. )]TJ
/T1_2 1 Tf
(2006;1\(3\):441-447.)Tj
/T1_0 1 Tf
-0.03 Tc 0.28 Tw /Span<>> BDC
-1.8 -1.2 Td
( )Tj
EMC
[(6)-30(.)]TJ
/Span<>> BDC
( )Tj
EMC
/T1_2 1 Tf
0 Tc 0.005 Tw 1.8 0 Td
[(Creer MH, Lau BW)149.9(, Jones JD)59.8(, Chan KM. Pyro)25(glutamic aci)]TJ
0 Tw (-)Tj
T*
(demia in an adult patient. )Tj
/T1_3 1 Tf
(Clin Chem. )Tj
/T1_2 1 Tf
(1989;35\(4\):684-686.)Tj
/T1_0 1 Tf
-0.03 Tc 0.28 Tw /Span<>> BDC
-1.8 -1.2 Td
( )Tj
EMC
[(7)-30(.)]TJ
/Span<>> BDC
( )Tj
EMC
/T1_2 1 Tf
0 Tc 0.078 Tw 1.8 0 Td
[(Mizock B)34.9(A, Bel)25(yae)24.9(v S, Mecher C. Une)14.9(xplained metabolic )]TJ
0.17 Tw T*
[(acidosis in criticall)25(y ill patients: the role of p)29.7(yro)25(glutamic )]TJ
0 Tw T*
(acid. )Tj
/T1_3 1 Tf
[(Intensive Car)37(e Med. )]TJ
/T1_2 1 Tf
(2004;30\(3\):502-505.)Tj
/T1_0 1 Tf
-0.03 Tc 0.28 Tw /Span<>> BDC
-1.8 -1.2 Td
( )Tj
EMC
[(8)-30(.)]TJ
/Span<>> BDC
( )Tj
EMC
/T1_2 1 Tf
0 Tc 0.006 Tw 1.8 0 Td
[(V)110.8(er)-19.7(ma R, P)39.8(olsani KR, )29.5(W)39.8(ilt J)59.8(, Loehrk)9.8(e ME. 5-Oxoprolinuria )]TJ
0.082 Tw T*
[(as )0.5(a cause )0.5(of )0.5(high anion )0.5(g)4.8(ap )0.5(metabolic )0.5(acidosis. )]TJ
/T1_3 1 Tf
20.17 0 Td
[(Br )0.5(J Clin )]TJ
0 Tw -20.17 -1.2 Td
(Pharmacol. )Tj
/T1_2 1 Tf
(2012;73\(3\):489-491.)Tj
/T1_0 1 Tf
-0.03 Tc 0.28 Tw /Span<>> BDC
-1.8 -1.2 Td
( )Tj
EMC
[(9)-30(.)]TJ
/Span<>> BDC
( )Tj
EMC
/T1_2 1 Tf
0 Tc 0.29 Tw 1.8 0 Td
[(Due)24.9(w)25(all )0.5(JL, )0.5(F)49.8(en)39.8(v)14.9(es )55.5(AZ, )0.5(Riche)14.9(y )0.5(DS, )50.3(T)35(ran )0.5(LD)59.8(, )0.5(Emmett )]TJ
0.234 Tw T*
[(M. 5-Oxoproline \(p)29.8(yro)24.9(glutamic\) acidosis associated with )]TJ
0.194 Tw T*
(chronic acetaminophen use. )Tj
/T1_3 1 Tf
[(Pr)44.9(oc \(Bayl Univ Med Cent\). )]TJ
/T1_2 1 Tf
0 Tw T*
(2010;23\(1\):19-20.)Tj
/T1_0 1 Tf
-1.8 -1.2 Td
(10.)Tj
/Span<>> BDC
1.22 0 Td
( )Tj
EMC
/T1_2 1 Tf
-0.03 Tw 0.58 0 Td
[(Emmett M. )54.7(Acetaminophen to)19.8(xicity and 5-o)19.8(xoproline \(p)29.8(yro)]TJ
0 Tw (-)Tj
0.099 Tw T*
[(glutamic acid\): a tale of tw)39.8(o c)14.9(ycles, one an )54.9(A)110.8(TP-depleting )]TJ
-0.041 Tw T*
[(futile c)14.9(ycle and the other a useful c)14.9(ycle. )]TJ
/T1_3 1 Tf
[(Clin J )59.5(Am Soc Neph)]TJ
0 Tw (-)Tj
T*
[(r)44.9(ol. )]TJ
/T1_2 1 Tf
(2014;9\(1\):191-200.)Tj
/T1_0 1 Tf
-1.8 -1.2 Td
(11.)Tj
/Span<>> BDC
1.22 0 Td
( )Tj
EMC
/T1_2 1 Tf
0.038 Tw 0.58 0 Td
[(Liss DB)29.8(, P)14.9(aden MS, Schw)24.9(arz ES, Mullins ME. )30(What is the )]TJ
0.069 Tw T*
[(clinical signi\037cance of 5-o)19.8(xoproline \(p)29.7(yro)25(glutamic acid\) in )]TJ
0.193 Tw T*
[(high anion g)4.9(ap metabolic acidosis follo)39.8(wing paracetamol )]TJ
0.416 Tw 28.2 43.535 Td
[(\(acetaminophen\) e)14.9(xposure? )]TJ
/T1_3 1 Tf
0.356 Tw [(Clin T)91.8(o)19.7(xicol )-59.6(\(Phila\). )]TJ
/T1_2 1 Tf
0 Tw 21.722 0 Td
(2013;)Tj
( )Tj
-21.722 -1.2 Td
(51\(9\):817-827.)Tj
/T1_0 1 Tf
-1.8 -1.2 Td
(12.)Tj
/Span<>> BDC
1.22 0 Td
( )Tj
EMC
/T1_2 1 Tf
0.16 Tw 0.58 0 Td
[(V)39.8(illano JH, O\222Connell CW)149.9(, L)69.8(y BT)99.9(, Schneir )54.5(A. Case \037les )]TJ
0.026 Tw T*
[(from )0.5(the )0.5(Uni)24.9(v)14.9(ersity )0.5(of )0.5(Califor)-19.7(nia )0.5(San )0.5(Die)14.9(go )0.5(Health )0.5(System )]TJ
0.007 Tw T*
[(F)49.8(ello)39.8(wship coma and se)24.9(v)14.9(ere acidosis: remember to consider )]TJ
0 Tw T*
(acetaminophen. )Tj
/T1_3 1 Tf
-0.06 Tw [(J )-60(Med T)91.8(o)19.8(xicol. )]TJ
/T1_2 1 Tf
0 Tw 12.603 0 Td
(2015;11\(3\):368-376.)Tj
/T1_0 1 Tf
0.02 Tc -0.02 Tw -14.403 -1.2 Td
(13.)Tj
/Span<>> BDC
1.28 0 Td
( )Tj
EMC
/T1_2 1 Tf
0.216 Tw 0.52 0 Td
[(Abkur )50.2(TM, Mohammed )30.1(W)149.9(, )55.3(Ali M, Casserl)24.9(y L. )55.2(Aceta)]TJ
0 Tc 0 Tw (-)Tj
0.02 Tc 0.367 Tw T*
[(minophen-induced anion g)4.9(ap metabolic acidosis sec)]TJ
0 Tc 0 Tw (-)Tj
0.02 Tc 0.094 Tw T*
[(ondar)-19.7(y to 5-o)19.8(xoproline: a case repor)-19.7(t. )]TJ
/T1_3 1 Tf
[(J Med Case Rep.)20( )]TJ
/T1_2 1 Tf
-0.02 Tw T*
(2014;8:409.)Tj
/T1_0 1 Tf
0 Tc 0 Tw -1.8 -1.2 Td
(14.)Tj
/Span<>> BDC
1.22 0 Td
( )Tj
EMC
/T1_2 1 Tf
0.184 Tw 0.58 0 Td
[(V)39.8(ichot )54.9(AA, Raste)15(g)4.8(ar )55(A. Use of anion g)4.9(ap in the e)24.9(v)24.9(alua)]TJ
0 Tw (-)Tj
0.051 Tw T*
(tion of a patient with metabolic acidosis. )Tj
/T1_3 1 Tf
[(Am J Kidne)9.8(y Dis. )]TJ
/T1_2 1 Tf
0 Tw T*
(2014;64\(4\):653-657.)Tj
/T1_0 1 Tf
-1.8 -1.2 Td
(15.)Tj
/Span<>> BDC
1.22 0 Td
( )Tj
EMC
/T1_2 1 Tf
0.192 Tw 0.58 0 Td
[(Kanji )0.5(HD)59.9(, )0.5(Mithani )0.5(S, )0.5(Boucher )0.5(P)160(, Dias )50.4(VC, )90.3(Y)139.9(arema )0.6(MC. )]TJ
0.264 Tw T*
[(Coma, metabolic acidosis, and methemo)25(globinemia in a )]TJ
0.313 Tw T*
[(patient with acetaminophen to)19.8(xicity)85(. )]TJ
/T1_3 1 Tf
[(J P)79.9(opul )60(Ther Clin )]TJ
0 Tw T*
(Pharmacol. )Tj
/T1_2 1 Tf
(2013;20\(3\):e207-211.)Tj
/T1_0 1 Tf
-1.8 -1.2 Td
(16.)Tj
/Span<>> BDC
1.22 0 Td
( )Tj
EMC
/T1_2 1 Tf
0.147 Tw 0.58 0 Td
[(Ar)-19.8(menian )0.6(P)159.9(, )0.6(Gerona )0.6(RR, )0.5(Blanc )0.6(PD)59.8(, )30.3(W)49.8(u )55.5(AH, )0.6(Mookherjee )]TJ
0.184 Tw T*
[(S. 5-o)19.8(xoprolinemia causing ele)25(v)24.9(ated anion g)4.9(ap metabolic )]TJ
0.031 Tw T*
(acidosis in the setting of acetaminophen use. )Tj
/T1_3 1 Tf
[(J Emer)25(g Med. )]TJ
/T1_2 1 Tf
0 Tw T*
(2012;43\(1\):54-57.)Tj
/T1_0 1 Tf
-1.8 -1.2 Td
(17.)Tj
/Span<>> BDC
1.22 0 Td
( )Tj
EMC
/T1_2 1 Tf
0.358 Tw 0.58 0 Td
[(La)39.8(wrence DT)99.9(, Bechtel LK, Charlton NP)160(, Holste)14.9(ge CP)159.9(. )]TJ
0.289 Tw T*
[(5-o)19.8(xoproline-induced anion g)4.9(ap metabolic acidosis after )]TJ
0.142 Tw T*
[(an )0.5(acute )0.5(acetaminophen )0.5(o)45(v)14.8(erdose. )]TJ
/T1_3 1 Tf
0.082 Tw 14.474 0 Td
[(J Am )-59.5(Osteopath Assoc. )]TJ
/T1_2 1 Tf
0 Tw -14.474 -1.2 Td
(2010;110\(9\):545-551.)Tj
/T1_0 1 Tf
-1.8 -1.2 Td
(18.)Tj
/Span<>> BDC
1.22 0 Td
( )Tj
EMC
/T1_2 1 Tf
0.064 Tw 0.58 0 Td
[(Holman )0.5(M, ter )0.5(Maaten JC. )0.5([Se)24.9(v)14.9(ere )0.5(metabolic acidosis )0.5(as a )]TJ
0.067 Tw T*
[(result )0.5(of )0.5(5-o)19.8(xoproline )0.5(in )0.5(acetaminophen )0.5(use]. )]TJ
/T1_3 1 Tf
0.007 Tw 18.848 0 Td
[(Ned T)34.9(ijdsc)14.9(hr )]TJ
0 Tw -18.848 -1.2 Td
(Geneeskd. )Tj
/T1_2 1 Tf
(2010;154:A1838.)Tj
/T1_0 1 Tf
-1.8 -1.2 Td
(19.)Tj
/Span<>> BDC
1.22 0 Td
( )Tj
EMC
/T1_2 1 Tf
0.285 Tw 0.58 0 Td
[(Rolleman EJ)59.9(, Hoor)-19.8(n EJ)59.8(, Didden P)159.9(, Zietse R. Guilty as )]TJ
0.132 Tw T*
[(char)17.9(ged: unmeasured urinar)-19.8(y anions in a case of p)29.8(yro)24.9(glu)]TJ
0 Tw (-)Tj
T*
(tamic acidosis. )Tj
/T1_3 1 Tf
(Neth J Med. )Tj
/T1_2 1 Tf
(2008;66\(8\):351-353.)Tj
/T1_0 1 Tf
-1.8 -1.2 Td
(20.)Tj
/Span<>> BDC
1.22 0 Td
( )Tj
EMC
/T1_2 1 Tf
0.17 Tw 0.58 0 Td
[(Hodgman MJ)59.8(, Hor)-19.8(n JF)129.9(, Stork CM, et al. Profound meta)]TJ
0 Tw (-)Tj
0.043 Tw T*
[(bolic acidosis and o)19.8(xoprolinuria in an adult. )]TJ
/T1_3 1 Tf
-0.017 Tw [(J )-60.1(Med T)91.8(o)19.8(xicol. )]TJ
/T1_2 1 Tf
0 Tw T*
(2007;3\(3\):119-124.)Tj
/T1_0 1 Tf
-1.8 -1.2 Td
(21.)Tj
/Span<>> BDC
1.22 0 Td
( )Tj
EMC
/T1_2 1 Tf
0.011 Tw 0.58 0 Td
[(T)79.8(ailor P)159.9(, Raman )49.9(T)99.9(, Gar)17.8(g)4.9(anta CL, et al. Recur)-29.7(rent high anion )]TJ
0.029 Tw T*
[(g)4.9(ap metabolic acidosis secondar)-19.7(y to 5-o)19.7(xoproline \(p)29.8(yro)24.9(glu)]TJ
0 Tw (-)Tj
T*
(tamic acid\). )Tj
/T1_3 1 Tf
[(Am J Kidne)9.8(y Dis. )]TJ
/T1_2 1 Tf
(2005;46\(1\):e4-10.)Tj
ET
endstream
endobj
32 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Subtype/Form>>stream
BT
0 0 0 1 k
/GS0 gs
/T1_0 1 Tf
0 Tc 0 Tw 0 Ts 100 Tz 0 Tr 8 0 0 8 36 45.1778 Tm
(The Southwest Respiratory and Critical Care Chronicles 2017;5\(17\):32\226\
37)Tj
ET
endstream
endobj
33 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Subtype/Form>>stream
0 0 0 1 K
0.5 w 4 M 0 j 0 J
/GS0 gs
q 1 0 0 1 36 59.8957 cm
0 0 m
540 0 l
S
Q
10 M
q 1 0 0 1 36 731.2762 cm
0 0 m
540 0 l
S
Q
BT
0 0 0 1 k
/TT0 1 Tf
0 Tc 0 Tw 0 Ts 100 Tz 0 Tr 8 0 0 8 36 742.5262 Tm
[(Acetaminophen, the Missing )35.8(Anion Gap in the Patient with Metabolic )35.7(Acidosis)]TJ
/Span<>> BDC
( )Tj
EMC
62.719 0 Td
(Pena et al.)Tj
ET
endstream
endobj
51 0 obj
<>
endobj
52 0 obj
<>
endobj
53 0 obj
<>stream
H\n0<롂ҒBh+q؏ 41Q~6:iH/m>ىXn= ـpElgnQL wi!(|$ΤNu+Wpʼ2w̙p,W{=A,=8(vPY 7nZ4;hq忴pє1sƲ\e<e
0 @
endstream
endobj
54 0 obj
<>stream
HlUX~WB۔H$N҄ KhQR1 &1rcRqk\fy<3{_k}
ip|W7<'̈H@~Q^ (adLu=A<`UQ1ylAё3ώ9C
cR1xψ
tw>HIt|oo>^Ot I}v=a?a^d|+x9HLv;ȵ&([Z!xoAV7@: 쬾а-@5~#:ޔjbݴ}s-[99nVnhóWNޝ}tGO^A6|#Gaq?
0q>yi>cf1*z91q s%&O^E,^tY\zu36dnܴ[~_dkwNn^~/~O~C%=vSey曳_X~۪W7u?xh"l8`uXx$.KQwz_}_0} :bp3x
[i
u.35~Nz}>??3%MӾ